Wednesday, December 6, 2023


Low-cost jaundice detector passes first trial in Africa

BiliSpec a low-cost, battery-powered reader designed to diagnose jaundice by immediately quantifying serum bilirubin levels from a small drop of whole blood, has successfully...

Daily aspirin reduces hep B virus-related liver cancer risk

Daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer, found a study presented this at The Liver...

Impact of behavioural factors on health and survival of HIV-HCV patients

Novel five-year study highlights importance of behaviours such as coffee drinking and not smoking on health and survival of HIV and HCV infected patients,...

Blood test predicts best therapy in HCV

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy.

Combination drug success with HCV genotype 1

In two studies, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis, achieved high rates of sustained virologic response after 12 weeks of treatment with a combination of direct-acting-antiviral drugs.

High HCV rate in African HIV patients

In the largest study of its kind to date, researchers found high levels of infection with hepatitis C (HCV) across Africa, particularly in people infected with HIV.

HCV combination therapies show promise

A number of new HCV combination therapies show promise.

Potential cure for HBV

Australian scientists have found a potential cure for hepatitis B virus (HBV) infections, with a promising new treatment proving 100% successful in eliminating the infection in pre-clinical models.

New HCV treatment guidelines

The European Association for the Study of the Liver (EASL) has released its latest hepatitis C treatment guidelines.

HBV vaccination must be expanded

The universal infant hepatitis B virus (HBV) vaccination needs further expansion to significantly reduce HBV transmission and liver disease mortality, according to an Imperial College London analysis.

NASH has 50% higher death rate than NAFLD

A population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

In-patient cirrhosis deaths plummet

The largest US sampling to date found 'dramatic improvements' in the survival of patients with cirrhosis and liver failure.

NAFLD promotes coronary artery calcification

Non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

HCV increases cancer risk 'significantly'

Cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort.